SolarEdge (SEDG) Is Down 22.9% After Cautious Q3 Guidance and Home-Backup Partnership Update

SolarEdge Technologies, Inc.

SolarEdge Technologies, Inc.

SEDG

0.00

  • SolarEdge Technologies recently reported second-quarter 2026 results, with sales rising to US$346.25 million and net loss narrowing to US$30.75 million, while also issuing third-quarter revenue guidance of US$310 million to US$340 million that excludes significant one-time items.
  • Separately, ConnectDER announced the full integration of its IslandDER Meter Socket Adapter with SolarEdge’s Nexis home energy system, aiming to simplify whole-home backup installations and reduce unexpected costs for U.S. homeowners and installers.
  • We’ll now examine how SolarEdge’s cautious third-quarter revenue guidance reshapes its existing investment narrative and medium-term expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

SolarEdge Technologies Investment Narrative Recap

To own SolarEdge today, you need to believe its Nexis-centric, solar plus storage model can eventually convert higher sales into sustainable profits, despite ongoing net losses and competitive pressure. The cautious third-quarter revenue guidance of US$310 million to US$340 million keeps short term expectations muted and underscores that the key near term catalyst remains any clear sign of margin stabilization, while persistent losses and volatility in demand remain the biggest risk. The guidance itself does not materially change that balance.

The ConnectDER integration with SolarEdge’s Nexis home energy system looks closely tied to that margin and demand story. By streamlining whole home backup installations and potentially reducing unexpected costs for U.S. homeowners and installers, it directly supports Nexis adoption, a core part of the thesis that integrated hardware and software can support better economics over time, even as the latest guidance reminds investors that profitability has yet to follow the recent revenue growth.

Yet beneath the Nexis promise, investors should be aware of the persistent pressure from low cost competitors and tariff related margin strain...

SolarEdge Technologies' narrative projects $1.7 billion revenue and $83.8 million earnings by 2029.

Uncover how SolarEdge Technologies' forecasts yield a $45.25 fair value, a 42% upside to its current price.

Exploring Other Perspectives

SEDG 1-Year Stock Price Chart
SEDG 1-Year Stock Price Chart

Before this Q3 guidance, the most optimistic analysts were modeling revenue growth of about 21.7 percent a year and earnings of roughly US$204.5 million by 2029, which is far more optimistic than the risk of shrinking U.S. residential demand and pricing pressure highlighted earlier, so it is worth asking whether this quarter’s cautious outlook could push those upbeat forecasts and your own expectations in very different directions.

Explore 4 other fair value estimates on SolarEdge Technologies - why the stock might be worth 45% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your SolarEdge Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free SolarEdge Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SolarEdge Technologies' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

  • Find 51 companies with promising cash flow potential yet trading below their fair value.
  • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.